Evaluating the In Vitro Activity of Depsidones from Usnea subfloridana Stirton as Key Enzymes Involved in Inflammation and Gout

Thanh-Trung Nguyen1, Srilakshmi Nallapaty2, G.S.N Koteswara Rao3, Sree Teja Koneru3, Satya Sowbhagya Priya Annam4, Vinay Bharadwaj Tatipamula1,2

1Institute of Research and Development, Duy Tan University, Da Nang 550000, Vietnam.  
2Faculty of Pharmacy, Duy Tan University, Da Nang 550000, Vietnam.  
3Pharmaceutical Sciences Department, K L College of Pharmacy, Koneru Lakshmaiah Education Foundation, Vaddeswaram – 522 502, Guntur, Andhra Pradesh, India.  
4Pharmaceutical Sciences Department, University College of Pharmaceutical Sciences, Andhra University, Visakhapatnam 530003, Andhra Pradesh, India.

Abstract

Background: Traditionally, Usnea genus has significant uses in the treatment of swelling and tumors in Africa and Asia. The aim of the present study was to investigate the chemical constituents present in the acetone extract (AE) of Usnea subfloridana Stirton and also to evaluate their anti-inflammatory and anti-gout effects.

Methods: Isolation and characterization of secondary metabolites from AE were evaluated by chromatography and spectral studies. Anti-inflammatory activities were assessed through cyclooxygenases (COX1 and COX2) and 5-lipooxygenase (5-LOX) enzyme inhibition assays, while anti-gout effects were evaluated by xanthine oxidase (XO) inhibition assay.

Results: The existence of five known depsidones, identified as galbinic acid (1), conprotocetraric acid (2), constictic acid (3), salazinic acid (4), and lobaric acid (5), were exposed by chemical investigation of AE and confirmed by spectral data. Using in vitro enzyme inhibition assays, it was noticed that all the isolates showed dose-dependent activity against all the tested enzymes. Mainly, compounds 2 and 5 showed better inhibition efficiency on COX2 enzyme with the IC50 of 7.17±1.07 and 7.01±0.94 nM, respectively, than the reference drug indomethacin (7.3±0.65 nM). Furthermore, all isolates exhibited potent inhibition effects on the XO enzyme.

Conclusion: The results indicated that U. subfloridana can be a favorable natural source for the treatment of inflammation and gout. Compounds 2 and 5 were responsible for these biological actions by regulating pro-inflammatory enzymes, namely COXs, 5-LOX, and XO.

Keywords: -5-Lipooxygenase  
-Anti-inflammation  
-Cyclooxygenase  
-Enzyme inhibition  
-Usnea subfloridana  
-Xanthine oxidase

Introduction

Inflammation is a normal response from the immune system to a lesion that heals the injured tissues or neutralizes the invaded pathogens. Though a self-limiting manner, inflammation can turn into chronic, which leads to many deadly diseases like Alzheimer’s, cancer, atherosclerosis, rheumatoid arthritis, and gout. The molecular and cellular level studies on inflammation identified two major metabolic pathways responsible for chronic inflammation. The cyclooxygenase (COX) pathway controls the production of prostacyclins, prostaglandins (PGs), and thromboxane (TXA2) by COX1 and COX2 enzymes. The lipooxygenase (LOX) channel alters the production of leukotrienes and hydroperoxy fatty acids by 5-LOX, 12-LOX, and 15-LOX enzymes.

Clinically, non-steroidal anti-inflammatory drugs (NSAIDs) were medications of choice to treat inflammation by inhibiting COX enzymes. Both COX1 and COX2 enzymes are entirely responsible for physiological production and biosynthesis of PGs and TXA2, but COX1 shows a fundamental role involved in the modulation of gastrointestinal, renal, and vascular functions. At the same time, COX2 regulates cytokines, endotoxins, and mitogens in inflammation, pain, and fever. These observations led to the development of selective COX2 inhibitor drugs. As a result, the introduction of highly selective COX2 inhibitors, well known as coxibs (celecoxib, rofecoxib, etc.), came into existence. But, the coxib series were noticed to have adverse lower gastrointestinal side effects. In 2004, FitzGerald, an American scientist, highlighted a cluster of suspected severe cardiovascular effects and increased risk of cardiovascular diseases emanating from the use of coxib drugs. Furthermore, several studies related to cardiovascular reactions with coxibs are under process. However, researchers are fascinating to design and develop...
novel anti-inflammatory agents with low toxicity and adverse effects.

On the other hand, the usage of natural sources like lichens and their extracts as anti-inflammatory agents is well known for ages. Based on the data of the folklore and publications on lichens, researchers tested lichens and their products for anti-inflammatory properties. They identified many therapeutic agents used to diagnosis acute and chronic inflammation with lesser side effects.

Usnea genus belongs to family Parmeliaceae, well recorded in the flora of Asia, and Africa. This genus consists of around 1000 species worldwide, many of them recorded in countries of Asia. Amongst these, Usnea subfloridana Stirton is a fruticose lichen, usually called “Beard lichen,” and “Old man’s beard” in Tamil Nadu, India. In the folklore of many Asian and African countries, Usnea species has been used in the treatment of a fever, skin diseases, swelling, sore throat, and tumors. Mainly, the Asian and African tribes used the species of Usnea in the treatment of chronic inflammation and arthritis. Biologically, U. subfloridana has been reported to have antibacterial and antifungal activities. Besides, no chemical examination has been performed on lichen U. subfloridana. Earlier, we have identified and reported the anti-inflammatory capabilities of secondary metabolites and extracts of some lichens. Thus, based on the reports of the folklore and publications on Usnea genus as good source for anti-inflammatory agents, the aim of present study is to examine the phytoconstituents present in the acetone extract of under-investigated lichen U. subfloridana (AE) employing chromatography and to monitor anti-inflammatory and anti-gout effects of identified secondary metabolites.

Materials and Methods

Lichen material

The lichen Usnea subfloridana Stirton (Family: Parmeliaceae) collected on the barks of alpine trees in Wenlock Downs 9th Mile Shooting Point (11º12’18” N and 76º59’92” E), Coimbatore-Ooty-Gundupet Hwy, Tamil Nadu, India, at 7300 ft. elevation, on 12 December 2018. The sample was authenticated by Dr. D. K. Upreti, Chief Scientist, CSIR-NBRI (National Botanical Research Institute), Lucknow, India, and a voucher specimen (18-035446) was deposited at Lichen herbarium, CSIR-NBRI, India.

Chemicals and reagent

5-Lipoxygenase (No. 437996), diclofenac, and xanthine oxidase (No. MAK078) purchased from Sigma Aldrich (USA), COX1 and COX2 (Cat. No.: 560131) purchased from Cayman (USA).

Extraction and isolation of compounds

About 100 g of U. subfloridana was shade dried and extracted with acetone at room temperature (3 times). All combined and evaporated under low pressure to obtain an acetone extract of U. subfloridana (AE, 5 g, 5%w/w). By using column chromatography (CC) of mesh size 100-200, AE extract (5 g) was fractionated using a hexane/ethyl acetate solvent system (step gradient flow from 100:0, 95:5, 90:10, ..., 5:95, 0:100), which yielded five main fractions, namely F1-5. Similarly, F1 (200 mg) subjected to CC using the above parameters yielded 1 (110 mg, 0.11%w/w) as colorless sharp needles. By using step gradient flow dichloromethane/ethyl acetate solvent system (from 100-0, 95-5, 90-10, ..., 5:95, 0:100), F2 (250 mg) gave 2 (120 mg, 0.12%w/w) as a pale yellow solid. Similarly, with dichloromethane/ethyl acetate solvent system, F3 (200 mg) yielded 3 (90 mg, 0.09%w/w) as colorless needles, F4 (800 g) yielded 4 (500 mg, 0.5%w/w) as pale yellowish needles, F5 (600 g) yielded 5 (400 mg, 0.4%w/w) as a faint yellow solid. Initially, all the compounds obtained in solid form, they are purified by subjected to re-crystallization using hexane and acetone (9:1). NMR [Bruker Avance 400 Spectrometer (400 MHz for 1H-NMR and 13C-NMR) and CNHS Organic Elemental Analyzer] analyses were applied for structure elucidation of isolated compounds.

In vitro assays of anti-inflammatory activity

Cyclooxygenase (COX1/2) inhibitory assay

The abilities of depsidones (1-5) to inhibit isoenzymes COX1-2 were performed using COX (ovine/human) inhibitor assay kit (Cayman, Cat. No.: 560131). To 10 µl of either COX1 or COX2 added 0.1 M Tris-HCl buffer (960 µl) and different concentrations of test samples and incubated at 37 ºC for 10 min. Later 10 µl of 100 µM arachidonic acid, after 2 min 1 M HCl of 50 µl and Ellman’s reagent, were added. The absorbance was noted spectrophotometrically at 410 nm against the blank. The % inhibition was deliberated with the absorbance values by which IC50 values were calculated by linear regression.

5-lipoxygenase (5-LOX) inhibitory assay

The depsidones (1-5) were tested against 5-LOX (human recombinant) using 5-LOX assay kit (No. 437996, Sigma Aldrich). To 90 µl of 5-LOX enzyme solution added different test sample concentrations, 100 µl of de chromogen, and finally added 10 µl of the substrate (arachidonic acid) and gently shake or 10 min and absorbance was recorded at 490 nm against the blank. The % inhibition was deliberated with the absorbance values by which IC50 values were calculated by linear regression.

Xanthine oxidase (XO) inhibitory assay

All the isolated depsidones (1-5) were subject to XO inhibitory assay using assay Sigma Aldrich assay kit. To 10 µl of the substrate (xanthine, 5 mM), added of sodium phosphate buffer (470 µl), different test sample concentrations, and 10 µl of XO enzyme and incubated for 5 min at 25 ºC and absorbance was recorded at 295 nm against the blank. The % inhibition was deliberated with the absorbance values by which IC50 values were calculated by linear regression.
Chemical and Biological Profile of *U. subfloridana*

Spectral data for isolated depsidones

Galbinic acid (1) - Colourless sharp needles (110 mg, 0.11%w/w); m.p. 262-263 ºC; 1H NMR (400 MHz, DMSO-$_d_6$): 1.98 (3H, s, 18-CH$_3$), 2.28 (3H, s, 20-CH$_3$), 5.27 (2H, s, 16-CH$_2$), 6.00 (1H, s, 5-Ar-H), 8.08 (1H, s, 11-Ar-H), 8.32 (1H, s, 14-OH), 8.52 (1H, s, 11-OH), 9.03 (1H, s, 4-OH), 9.52 (1H, s, 11-CHO); 13C NMR (400 MHz, DMSO-$_d_6$): 22.14 (C-18), 22.21 (C-20), 60.90 (C-16), 97.59 (C-11), 113.70 (C-1), 114.46 (C-3), 116.57 (C-13), 117.49 (C-5), 127.42 (C-15), 137.09 (C-10), 144.02 (C-9), 152.53 (C-8), 152.94 (C-6), 158.93 (C-14), 163.16 (C-7), 165.75 (C-2), 167.57 (C-4), 167.72 (C-12), 172.77 (C-17), 188.38 (C-19); CHNS analysis for galbinic acid [C$_{20}$H$_{14}$O$_{11}$]: C-55.98, H-3.29(%), calcd. C-55.82, H-3.28(%).

Conprotocetraric acid (2) - Pale yellow solid (120 mg, 0.12%w/w); m.p. 234-235 ºC; 1H NMR (400 MHz, DMSO-$_d_6$): 2.29 (3H, s, 14-CH$_3$), 2.85 (3H, s, 15-CH$_3$), 5.03 (2H, s, 17-CH$_2$), 5.31 (2H, s, 18-CH$_2$), 6.50 (1H, s, 12-Ar-H), 7.30 (1H, s, 11-OH), 8.03 (1H, s, 18-OH), 8.65 (1H, s, 5-OH), 8.97 (1H, s, 17-OH), 9.17 (1H, s, 16-COOH); 13C NMR (400 MHz, DMSO-$_d_6$): 14.02 (C-15), 22.21 (C-14), 58.06 (C-18), 58.41 (C-17), 114.67 (C-8), 117.30 (C-12), 117.39 (C-10), 120.27 (C-4), 126.29 (C-6), 142.02 (C-3), 146.12 (C-2), 147.96 (C-1), 149.36 (C-13), 160.25 (C-5), 163.16 (C-7), 164.24 (C-9), 164.72 (C-11), 174.00 (C-16); CHNS analysis for conprotocetraric acid [C$_{16}$H$_{15}$O$_{5}$]: C-57.74, H-4.14(%), calcd. C-57.45, H-4.29(%).

Salazinic acid (4) - Pale yellowish needles (500 mg, 0.5%w/w); m.p. 274-275 ºC; 1H NMR (400 MHz, DMSO-$_d_6$): 2.55 (2H, s, 18-CH$_3$), 4.93 (2H, s, 16-CH$_2$), 6.57 (1H, s, 5-Ar-H), 7.28 (1H, s, 16-Ar-H), 7.62 (1H, s, 11-OH), 8.08 (1H, s, 11-Ar-H), 8.46 (1H, s, 14-OH), 8.92 (1H, s, 4-OH), 9.46 (1H, s, 17-CHO); 13C NMR (400 MHz, DMSO-$_d_6$): 22.21 (C-18), 58.40 (C-16), 97.59 (C-11), 113.70 (C-1), 114.46 (C-3), 114.82 (C-13), 117.49 (C-5), 130.01 (C-15), 136.07 (C-10), 142.81 (C-9), 152.94 (C-6), 154.57 (C-8), 161.01 (C-14), 163.17 (C-7), 165.75 (C-2), 167.57 (C-4), 167.72 (C-12), 188.37 (C-17); CHNS analysis for salazinic acid [C$_{18}$H$_{12}$O$_{10}$]: C-55.57, H-3.20(%), calcd. C-55.68, H-3.12(%).

Lobaric acid (5) - Faint yellow solid (400 mg, 0.4%w/w); m.p. 196-197 ºC; 1H NMR (400 MHz, DMSO-$_d_6$): 0.85 (3H, s, 24-CH$_3$), 0.86 (3H, s, 19-CH$_3$), 1.20-1.26 (6H, m, 18,22,23-CH$_3$), 1.39-1.42 (2H, m, 17-CH$_2$), 1.47-1.52 (2H, m, 21-CH$_2$), 2.48-2.51 (2H, t, J= 4, 8 Hz, 16-CH$_2$), 3.11-3.14 (2H, t, J= 4, 8 Hz, 20-CH$_3$), 3.68 (3H, s, 14-CH$_3$), 6.72 (1H, s, 13-Ar-H), 6.82 (1H, s, 3-Ar-H), 6.86 (1H, s, 5-Ar-H), 7.68 (1H, s, 12-OH), 8.56 (1H, s, 25-COOH); 13C NMR (400 MHz, DMSO-$d_6$): 12.12 (C-19/24), 20.28 (C-18), 21.04 (C-23), 26.76 (C-17), 28.16 (C-21), 28.74 (C-22), 29.45 (C-20), 38.84 (C-16), 54.14 (C-14), 104.19 (C-13), 106.48 (C-3), 108.63 (C-5), 108.74 (C-11), 112.94 (C-1), 136.02 (C-10), 139.31 (C-9), 142.27 (C-6), 146.43 (C-8), 157.57 (C-2), 157.78 (C-12), 160.21 (C-7), 162.02 (C-4), 169.95 (C-25), 200.51 (C-15); CHNS analysis for lobaric acid [C$_{20}$H$_{18}$O$_{8}$]: C-65.40, H-6.10(%), calcd. C-65.78, H-6.18(%).

**Results**

**Chemical constituents**

Five known depsidones (1-5) were successfully isolated and identified from the acetone extract of *U. subfloridana* (AE) for the first time by utilizing chromatographic and re-crystallization methods and analyses of their spectral NMR data and elemental composition. The obtained data were interrelated with those reported in the previous literature (Figure 1).

**Statistical analysis**

The percentage of inhibition outcomes of the current study were denoted as mean±SD, employing one-way ANOVA followed by a t-test, where $p < 0.05$ was statistical significance.

![Figure 1. Known depsidones (1-5) isolated from acetone extract of *Usnea subfloridana* Stirton.](image-url)
**Anti-inflammatory activity**

The *in vitro* anti-inflammatory (Table S1-S2) and anti-gout (Table S3) effects of isolated depsidones (1-5) were performed using COX-1/2, 5-LOX, and XO enzymes and the results were reported in IC\textsubscript{50} values (Table 1). The concentration required for 50% inhibition of COX1 enzyme for compounds 1, 2, 3, 4 and 5 found to be 18.9±1.20, 11.9±1.12, 21.5±2.73, 15.7±1.03 and 17.1±1.24 nM, respectively, whereas reference drug, indomethacin with 7.3±0.44 nM (Table 1). From the results of COX2 enzyme inhibitory assay, it is noticed that the compounds 2 and 5 showed potent inhibition efficiency on COX2 enzyme with the IC\textsubscript{50} of 7.17±1.07 and 7.01±0.94 nM, respectively, compared to indomethacin with 7.3±0.65 nM (Table 1). Moreover, the IC\textsubscript{50} values of compound 1, 3, and 4 on COX2 found to be 11.9±1.30, 21.8±1.75, and 18.5±1.21 nM, respectively, while indomethacin with 7.30±0.65 nM (Table 1).

The concentration of 1, 2, 3, 4 and 5 needed to inhibit 5-LOX activity at 50% was found to be 21.8±1.35, 11.4±1.59, 19.3±1.55, 22.4±2.03 and 16.6±1.30 nM, respectively, while that of diclofenac was 9.4±0.52 nM, respectively (Table 1). Except compound 3, all the isolated depsidones 1, 2, 4 and 5 showed noteworthy inhibition of XO enzyme with IC\textsubscript{50} values of 13.0±1.40, 14.6±1.02, 19.3±1.55 and 18.9±1.20 nM, respectively, while allopurinol with 2.25±0.15 nM (Table 1). The concentration of 3 required for 50% reticence of the XO enzyme was found to be 24.6±2.17 nM (Table 1).

**Discussion**

Lichens are recognized as an integral part of all ecosystems that can colonize and grow on bare rock surfaces, soil, trees, or even in intertidal zones and freshwater streams.\(^{14,16}\) It has been reasoning that lichens produced unique substances that support their survival and growth in extreme conditions. Different groups have applied chromatography techniques to analyze lichen extracts and elucidated approximately 1050 unique phytoconstituents, to date, which falls in the classes of carbohydrates, amino-acid derivatives, chromones, xanthones, anthraquinones and naphthoquinones, depsides, tridepsides, depsidones, steroids, etc.\(^{18}\)

Among all classes of lichen constituents, depsidones are the most remarkable secondary metabolites, comprising of two 2,4-dihydroxybenzoic acid rings connected by both ester and ether bonds. Also, they are well-acknowledged to have antibacterial, antifungal, antioxidant, anti-inflammatory, and cytotoxic properties.\(^{29}\) On the other hand, the *Usnea* genus is the biggest of the fruticose lichens comprising about 1000 species around the world. The studies on species of *Usnea* are well-reported to have a significant content of depsidones such as usnic acid, galbinic acid, salazinic acid, conprotocetraric acid, and constictic acid, etc. Previously, these compounds are screened for their antimicrobial and antioxidant activities.\(^{30}\)

In our phytochemical analysis of the acetone extract of the lichen *U. subflorida* (AE) yielded five known depsidones (1-5), which affords novel data on the chemical profile of *U. subflorida*. Previously, galbinic acid (1) was isolated from *Usnea undulata* Stirt., conprotocetraric acid (2) was isolated from *Usnea trichodeoides* Vain., constictic acid (3) was isolated from *Usnea aciculifera* Vain., salazinic acid (4) and lobaric acid (5) were isolated from *Usnea barbata*.\(^{27}\) The *in vitro* enzymatic screening of these depsidones (1-5) from *U. subflorida* proved its aptitude to treat inflammation and gout. It was even justifying that compounds 2 and 5 have potent inhibition of COX2 and XO enzymes.

As said earlier, inflammatory is regulated by higher levels of eicosanoids, namely prostaglandins, thromboxanes, and leukotrienes in the human body. COXs and 5-LOX are key enzymes that catalyzes the production of prostaglandins, thromboxanes and leukotrienes, and hydroperoxy fatty acids from arachidonic acid.\(^{31}\) Particularly, inhibition of any one of the eicosanoids will activate the other pathway and prolongs inflammation. For instance, inhibition of only prostaglandins will lead to elevated levels of leukotrienes by activation of the alternative path, i.e., 5-LOX pathway. Thus, routes of COXs and 5-LOX are chosen for the rate-limiting steps to reduce pain, as well as inflammation. Therefore, COX and 5-LOX (dual inhibitors) drugs inhibit the production of eicosanoids (prostaglandins, thromboxanes, and leukotrienes) and entirely prevent inflammation by lesser adverse effects.\(^{32,33}\) Generally, NSAIDs are the drugs of choice to control the production of eicosanoids, and eventually relief from inflammation.\(^{32}\) The outcomes of our study exhibited that isolated depsidones (1-5) act as a dual

**Table 1.** IC\textsubscript{50} values of 1-5 against Cyclooxygenase (COX1 and COX2), 5-lipoxygenase (5-LOX) and xanthine oxidase (XO) enzymes.

| Sample | IC\textsubscript{50} values (nM)* |
|--------|---------------------------------|
|        | COX1   | COX2   | 5-LOX | XO     |
| 1      | 18.9±1.20 | 11.9±1.30 | 21.8±1.35 | 13.00±1.40 |
| 2      | 11.9±1.12 | 7.17±1.07 | 11.40±1.59 | 14.60±1.02 |
| 3      | 21.5±2.73 | 21.80±1.75 | 19.30±1.55 | 24.60±2.17 |
| 4      | 15.70±1.03 | 18.50±1.21 | 22.40±2.03 | 19.30±1.68 |
| 5      | 17.10±1.24 | 7.01±0.94 | 16.60±1.30 | 14.60±1.35 |
| *n=3, mean ± SD values* | | | | |

294 | *Pharmaceutical Sciences, 2021, 27(2), 291-296*
Chemical and Biological Profile of *U. subfloridana*

(1-5), which is available on the journal's web site along with the published article.

References
1. Huang MY, Lin J, Huang ZJ, Xu HG, Hong J, Sun PH, et al. Design, synthesis and anti-inflammatory effects of novel 9-O-substituted-berberine derivatives. Med Chem Comm. 2016;7(4):658-66. doi:10.1039/C5MD00577A
2. Ferrero-Miliani L, Nielsen OH, Andersen PS, Girardin SE. Chronic inflammation: importance of NOD2 and NALP3 in interleukin-1β generation. Clin Exp Immunol. 2007;147(2):227-35. doi:10.1111/j.1365-2249.2006.03261.x
3. Chen LZ, Sun WW, Bo L, Wang JQ, Xiu C, Tang WJ, et al. New arylypyrazoline-coumarins: Synthesis and anti-inflammatory activity. Eur J Med Chem. 2017;138:170-81. doi:10.1016/j.ejmech.2017.06.044
4. Lu XY, Wang ZG, Ren SZ, Shen FQ, Man RJ, Zhu HL. Coumarin sulfonamides derivatives as potent and selective COX-2 inhibitors with efficacy in suppressing cancer proliferation and metastasis. Bioorg Med Chem Lett. 2016;26(15):3491-8. doi:10.1016/j.bmcl.2016.06.037
5. Alekhy, Santhoshi AH, Hymavathi K, Bharadwaj VT. In-vitro cytotoxicity study of mangilcolous lichens, *Graphis ajarekarii* Patw. & CR Kulk., and *Parmotrema tinctorum* (Despr. ex Nyl.). Amer J Med Nat Sci. 2020;1(1):25-9.
6. Libby P. Inflammation in atherosclerosis. Nature. 2002;420(6917):687-74. doi:10.1038/nature01323
7. Kim HY, Kim HV, Jo S, Lee CJ, Choi SY, Kim DJ, Kim Y. EPPS rescues hippocampus-dependent cognitive deficits in APP/PS1 mice by disaggregation of amyloid-β oligomers and plaques. Nat Commun. 2015;6(1):1-4. doi:10.1038/ncomms10755
8. Rommel C, Camps M, Ji H. PI3Kδ and PI3Kγ: partners in crime in inflammation in rheumatoid arthritis and beyond? Nat Rev Immunol. 2007;7(3):191-201. doi:10.1038/nri2036
9. Chan KY, Mohamad K, Ooi AJ, Isimyabir Z, Chung L. Bioactivity-guided fractionation of the lipoxigenase and cyclooxygenase inhibiting constituents from *Chisocheton polyanthus* Merr. Fitoterapia. 2012;83(5):961-7. doi:10.1016/j.fitote.2012.04.018
10. Velázquez CA, Chen QH, Citro ML, Keefer LK, Knaus EE. Second-generation aspirin and indomethacin produgs possessing an O 2-(Acetoxymethyl)-1-(2-carboxypyrrrolidin-1-yl) diazenium-1, 2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J Med Chem. 2008;51(6):1954-61. doi:10.1021/jm701450q
11. Rainsford KD. Anti-inflammatory drugs in the 21st century. In: Inflammation in the pathogenesis of chronic diseases. Dordrecht: Springer; 2007. p. 3-27. doi:10.1007/1-4020-5688-5_1
12. FitzGerald GA. Coxibs and cardiovascular disease. N Engl J Med. 2004;351(17):1709-11. doi:10.1056/NEJMip049288
13. Palkar MB, Singhai AS, Ronad PM, Vishwanathswamy AH, Boreddy TS, Veerapur VP, et al. Synthesis, pharmacological screening and in silico studies of new class of diclofenac analogues as a promising anti-inflammatory agents. Bioorg Med Chem. 2014;22(10):2855-66. doi:10.1016/j.bmc.2014.03.043
14. Bharadwaj VT, Sastry GV, Murthy KS. A note on the occurrence of lichens on Vainateya Godavari mangroves

Pharmaceutical Sciences, 2021, 27(2), 291-296 | 295
Nguyen et al.

in East Godavari district of Andhra Pradesh India. Stud Fungi. 2018;3(1):302-8. doi:10.5943/sif/3/1/30

15. Shukla P, Upreti DK, Tewari LM. Secondary metabolite variability in lichen genus Usnea in India: A potential source for bioprospection. G-J Environ Sci Technol. 2015;2(4):44-55.

16. Bharadwaj V. New record of mangrove lichens from Andhra Pradesh and Orissa states of India. Stud Fungi. 2019;4(1):90-93. doi:10.5943/sif/4/1/12

17. Sharnoff S. A field guide to California lichens. New Haven: Yale University Press; 2014.

18. Tatipamula VB. Chemical and pharmacological evaluation of manglicolous lichens. Saarbrücken: Lambert Academic Publishing; 2019. p. 1-72

19. Çobanoğlu G, Sesal C, Açıkgöz B, Karalý I. Evaluation of antimicrobial activity of the lichens Physcia aipolia, Xanthoria parietina, Usnea florida, Usnea subfloridana and Melanohalea exasperata. Mod Phytopharm. 2016;10:19-24. doi:10.5281/zenodo.155349

20. Tatipamula VB, Vedula GS. Anti-inflammatory properties of Dirinaria consimilis extracts in albino rats. J Biomed Sci. 2017;4(1):3-8. doi:10.3126/jbs.v4i1.20572

21. Tatipamula VB, Vedula GS. In vitro anti-inflammatory and cytotoxicity studies of two mangrove associated lichens, Dirinaria consimilis and Ramalina leiodae extracts. Hygeia J D Med. 2018;10(1):16-26. doi:10.15254/H.J.D.Med.2018.10.174

22. Tatipamula VB, Vedula GS, Sastry AV. Antarvediside AB from manglicolous lichen Dirinaria consimilis (Stirton) DD Awasthi and their pharmacological profile. Asian J Chem. 2019;31(4):805-12. doi:10.14233/ajchem.2019.21734

23. Tatipamula VB, Vedula GS, Sastry AV. Chemical and pharmacological evaluation of manglicolous lichen Roccella montagnei Bel em. DD Awasthi. Future J Pharm Sci. 2019;5(1):8. doi:10.1186/s43094-019-0009-6

24. Tatipamula VB, Vedula GS. Fibrinolytic, anti-inflammatory and cytotoxic potentials of extracts and chemical constituents of manglicolous lichen, Graphis ajarekarii Patw. & CR Kulk. Nat Prod J. 2020;10(1):87-93. doi:10.2174/221031550866618060410183

25. Selvam C, Jachak SM. A cyclooxygenase (COX) inhibitory biflavonoid from the seeds of Semecarpus anacardium. J Ethnopharmacol. 2004;95(2-3):209-12. doi:10.1016/j.jep.2004.07.026

26. Lee EJ, Kim JS, Kim HP, Lee JH, Kang SS. Phenolic constituents from the flower buds of Lonicerajaponica and their 5-lipoxygenase inhibitory activities. Food Chem. 2010;120(1):134-9. doi:10.1016/j.foodchem.2009.09.088

27. Owen PL, Johns T. Xanthine oxidase inhibitory activity of northeastern North American plant remedies used for gout. J Ethnopharmacol. 1999;64(2):149-60. doi:10.1016/S0378-8741(98)00119-6

28. Huneck S, Yoshimura I. Data of lichen substances. In: Identification of lichen substances. Heidelberg: Springer; 1996. p. 125-466. doi:10.1007/978-3-642-85243-5_3

29. Ibrahim SR, Mohamed GA, Al Haidari RA, El-Kholy AA, Zayed MF, Khayat MT. Biologically active fungal depsidones: Chemistry, biosynthesis, structural characterization, and bioactivities. Fitoterapia. 2018;129:317-65. doi:10.1016/j.fitote.2018.04.012

30. Dandapat M, Paul S. Secondary metabolites from lichen Usnea longissima and its pharmacological relevance. Pharmacognosy Res. 2019;11(2):103. doi:10.4103/pr.pr_111_18

31. Naidu KK, Priya SSA, Bharadwaj VT. In-vitro anti-inflammatory and anticancer activities of Octoblepharum albidum Hedw. Am J Med Nat Sci. 2020;1(1):19-24.

32. Canali R, Comitato R, Schonlau F, Virgili F. The anti-inflammatory pharmacology of Pycnogenol® in humans involves COX-2 and 5-LOX mRNA expression in leukocytes. Int Immunopharmacol. 2009;9(10):1145-9. doi:10.1016/j.intimp.2009.06.001

33. Mazumder S, De R, Sarkar S, Siddiqui AA, Saha SJ, Banerjee C, et al. Selective scavenging of intramitochondrial superoxide corrects diclofenac-induced mitochondrial dysfunction and gastric injury: A novel gastroprotective mechanism independent of gastric acid suppression. Biochem Pharmacol. 2016;121:33-51. doi:10.1016/j.bcp.2016.09.027

34. Sastry AV, Vedula GS, Tatipamula VB. In-vitro biological profile of mangrove associated lichen, Roccella montagnei extracts. Inven Rapid Ethnopharmacol. 2018;2018(3):153-8.

35. Booth VH. The specificity of xanthine oxidase. Biochem J. 1938;32(3):494-502. doi:10.1042%2Fbj0320494

36. Ragab G, Elshahaly M, Bardin T. Gout: An old disease in new perspective–A review. J Adv Res. 2017;8(5):495-511. doi:10.1016/j.jare.2017.04.008

37. Tatipamula VB, Killari KN, Prasad K, Rao GS, Talluri MR, Vantuku S, et al. Cytotoxicity studies of the chemical constituents from marine algae Chara baltica. Indian J Pharm Sci. 2019;81(5):815-23. doi:10.36468/pharmaceutical-sciences.575

38. Haritha P, Patnaik SK, Tatipamula VB. Chemical and pharmacological evaluation of manglicolous lichen Graphis ajarekarii Patw. & CR Kulk. Vietnam J Sci Technol. 2019;57(3):300-8. doi:10.15625/2525-2518/57/3/13679

39. Pétrilli V, Martinon F. The inflammasome, autoinflammatory diseases, and gout. Joint Bone Spine. 2007;74(6):571-6. doi:10.1016/j.jbspin.2007.04.004

40. Edwards NL. Gout. In: Klippel JH, Stone JH, Crofford, Le, White PH. editors. Primer on the rheumatic diseases. New York: Springer; 2008. p. 241-62. doi:10.1007/978-0-387-68566-3_12